NCT05872282招募中不适用
Feasible Study on a New Technique of ZIPPER Aortic Arch Stentgraft System in the Treatment of Aortic Arch Disease
Hangzhou Endonom Medtech Co., Ltd.3 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2023年4月28日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 24
- 试验地点
- 3
- 主要终点
- Freedom from major device/procedure-related adverse events within 30 days post-operation.
研究概览
简要总结
This study is the feasible study on a new technique of ZIPPER aortic arch stentgraft system
详细描述
The feasible study of ZIPPER aortic arch stentgraft system is a prospective, multicenter, single arm trial, which will enroll a total of 24 patients. The goal of this study is to evaluate the safety and efficacy of ZIPPER aortic arch stentgraft system in the treatment of patients with aortic arch disease, included aortic arch dissections, aneurysms, residual dissection following ascending aorta surgical operation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 18 to 80 years old
- •Patients diagnosed with aortic arch disease requiring intervention, including non-A-non-B aortic dissection, or residual dissection after type A ascending aortic repair; aortic arch aneurysms.
- •Patients with suitable vascular conditions, including:
- •Ascending aorta (including surgical graft) length greater than 30 mm (from the aortic sinusoid junction to the proximal cardiac margin of the innominate artery).
- •Proximal anchoring zone diameter ≥ 24 mm and ≤ 47 mm;
- •Proximal anchoring zone length ≥ 20 mm;
- •Innominate artery, left common carotid artery and left subclavian artery diameter ≤ 24 mm and ≥ 7 mm, length ≥ 20 mm；
- •Suitable arterial access for endovascular interventional treatment;
- •Patients able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the subject him/herself or his or her legal representative, and willing to complete follow-up visits as required under the protocol.
- •Evaluated by at least two investigators that the subjects are high-risk patients with more complications, poor general condition, high risk of deep hypothermic circulatory arrest, and not suitable for total arch replacement and other surgical procedures.
排除标准
- •Previously received open surgery or endovascular intervention for descending aorta or abdominal aorta;
- •Infectious aortic disease, takayasu arteritis, Marfan syndrome (or other connective tissue diseases );
- •Patients that have experienced systemic infection within past three months;
- •Neck surgery was performed within past three months;
- •Patients with severe stenosis, calcification, thrombosis or tortuosity in the brachiocephalic trunk, left common carotid artery or left subclavian artery;
- •Patients with intestinal necrosis and lower limb ischemic necrosis;
- •Paraplegic patients;
- •Heart transplant patients;
- •Patients that have suffered MI or stroke within past three months;
- •Patients with Class IV heart function (NYHA classification) or LVEF<30%
- •Active peptic ulcers or upper gastrointestinal bleeding occurring within the past three months;
- •Hematological abnormality, defined as follows: Leukopenia (WBC < 3 × 109/L), anemia (Hb < 90 g/L); coagulation dysfunction, thrombocytopenia (PLT count< 50 × 109/L);
- •Patients with renal insufficiency， serum creatinine > 150 umol/L (or 3.0 mg/dl) and / or end-stage renal disease requiring dialysis, shall be determined by the investigator after a comprehensive analysis;
- •Patients with severe liver dysfunction: ALT or AST exceeding 3 times the upper limit of norma, serum total bilirubin (STB) exceeds 2 times the upper limit of normal;
- •Patients who are allergic to contrast agents;
- •Patients that are pregnant or breastfeeding;
- •Patients with severe comorbidities who cannot tolerate anesthesia and surgery;
- •Patients with a life expectancy of less than 12 months;
- •Patients currently participating in other drug or device study;
- •The investigator assessed that the patient was ineligible for the study for other diseases or abnormalities.
结局指标
主要结局
Freedom from major device/procedure-related adverse events within 30 days post-operation.
时间窗: 30 days after intervention
Device or procedure related major adverse events included: stroke, respiratory failure, pericardial tamponade, dissection or aneurysm rupture, paraplegia, stent occlusion, fracture, migration, access vessel thrombosis or rupture, conversion to open surgery, death.
次要结局
- Postoperative branch vessel patency rate.(1 month, 6 months and 12 months post-intervention)
- Incidence of Type I or Type III endoleaks.(1 month, 6 months and 12 months post-intervention)
- Aortic-related mortality at 12 months post operation.(within 12 months post-intervention)
- All-cause mortality and major stroke within 12 months post-procedure.(within 12 months post-intervention)
- Incidence of device-related adverse events.(within 12 months post-intervention)
- Immediate postoperative technical success.(immediately after intervention)
- Results of aortic remodeling after aortic dissection surgery(1 month, 6 months and 12 months post-intervention)
- Incidence of surgically induced de novo aortic dissection converted to open-heart surgery or secondary intervention.(within 12 months post-intervention)
- Incidence of aortic arch stent graft migration.(1 month, 6 months and 12 months post-intervention)
- Progression control of aortic aneurysm(1 month, 6 months and 12 months post-intervention)
- Incidence of severe adverse events.(within 12 months post-intervention)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
不适用
Simulation of Stent-graft Deployment in Aortic Arch AneurysmsAortic Arch AneurysmNCT04244188Centre Hospitalier Universitaire de Saint Etienne4
已完成
不适用
ACURATE Neo™ TA Delivery System in Patient With Severe Aortic StenosisAortic StenosisNCT02950428Symetis SA60
Unknown
不适用
Evaluation of Mechanical Stapler for Aortic AnastomosesLeriche SyndromeAortic Aneurysm, AbdominalNCT00319475SVSE 2000 Ltd.10
已完成
不适用
DARTS I: Feasibility, Safety, and Performance TrialAcute DeBakey I Aortic DissectionIntramural HematomaNCT03397251Ascyrus Medical LLC.7
已完成
不适用
DARTS I Feasibility StudyAortic DissectionIntramural HematomaNCT03035643Ascyrus Medical LLC.40